Hikma Pharmaceuticals (LON:HIK) Earns “Buy” Rating from Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a research note issued to investors on Friday, Digital Look reports. They currently have a GBX 2,025 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 27.36% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on HIK. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Berenberg Bank boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Citigroup upped their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 2,085.83.

Hikma Pharmaceuticals Price Performance

Shares of Hikma Pharmaceuticals stock traded down GBX 35 during trading on Friday, hitting GBX 1,590. 275,001 shares of the company were exchanged, compared to its average volume of 4,574,925. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,865. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The firm has a 50 day moving average price of GBX 1,602.90 and a 200 day moving average price of GBX 1,476.30. The stock has a market capitalization of £3.29 billion, a price-to-earnings ratio of 9.03, a P/E/G ratio of 2.38 and a beta of 0.66.

Insiders Place Their Bets

In related news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.26% of the company’s stock.

Trending Headlines about Hikma Pharmaceuticals

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Jefferies reaffirmed its “buy” rating and set a GBX 2,025 price target, implying meaningful upside from recent trading levels. The recommendation reinforces confidence in Hikma’s outlook and is likely supporting investor sentiment. Jefferies reaffirms buy rating and price target
• Positive Sentiment: Rebecca Hall has been appointed chief financial officer and executive director. Hall joins from ViiV Healthcare, where she was a senior finance leader. Her appointment may be viewed positively because of her pharmaceutical-sector experience and could strengthen Hikma’s financial and strategic execution. Hikma appoints Rebecca Hall as CFO
• Neutral Sentiment: Current CFO Khalid Nabilsi is stepping down as Hall becomes his successor. The transition is a notable governance and management change, but the available reports do not indicate operational disruption or a change to Hikma’s financial guidance. Hikma CFO transition

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.